These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29956453)

  • 21. A new futility test approach in clinical interim data monitoring.
    Xue D
    Pharm Stat; 2012; 11(6):468-75. PubMed ID: 23015479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration.
    Green DJ; Liu XI; Hua T; Burnham JM; Schuck R; Pacanowski M; Yao L; McCune SK; Burckart GJ; Zineh I
    Clin Pharmacol Ther; 2018 Nov; 104(5):983-988. PubMed ID: 29218740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decision-making in early clinical drug development.
    Frewer P; Mitchell P; Watkins C; Matcham J
    Pharm Stat; 2016 May; 15(3):255-63. PubMed ID: 26991401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS).
    Nakonezny PA; Mayes TL; Byerly MJ; Emslie GJ
    J Psychiatr Res; 2015 Sep; 68():346-53. PubMed ID: 26028546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ignorance is not bliss: Statistical power is not probability of trial success.
    Zierhut ML; Bycott P; Gibbs MA; Smith BP; Vicini P
    Clin Pharmacol Ther; 2016 Apr; 99(4):356-9. PubMed ID: 26331445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian methodology for the design and interpretation of clinical trials in critical care medicine: a primer for clinicians.
    Kalil AC; Sun J
    Crit Care Med; 2014 Oct; 42(10):2267-77. PubMed ID: 25226118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet.
    Bender A; Cortés-Ciriano I
    Drug Discov Today; 2021 Feb; 26(2):511-524. PubMed ID: 33346134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analytical approach to assess the predictive value of biomarkers in Phase II decision making.
    Nikolakopoulos S; van der Wal WM; Roes KC
    J Biopharm Stat; 2013; 23(5):1106-23. PubMed ID: 23957519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two approaches to incorporate clinical data uncertainty into multiple criteria decision analysis for benefit-risk assessment of medicinal products.
    Wen S; Zhang L; Yang B
    Value Health; 2014 Jul; 17(5):619-28. PubMed ID: 25128056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method.
    Pritchett YL; Tamura R
    Pharm Stat; 2008; 7(3):170-8. PubMed ID: 17538942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint.
    Hong S; Shi L
    Stat Med; 2012 Apr; 31(9):831-43. PubMed ID: 22302442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporating uncertainty regarding applicability of evidence from meta-analyses into clinical decision making.
    Kriston L; Meister R
    J Clin Epidemiol; 2014 Mar; 67(3):325-34. PubMed ID: 24332396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The perils with the misuse of predictive power.
    Dallow N; Fina P
    Pharm Stat; 2011; 10(4):311-7. PubMed ID: 20967762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.
    Tunis SR; Stryer DB; Clancy CM
    JAMA; 2003 Sep; 290(12):1624-32. PubMed ID: 14506122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bayesian paradigm for decision-making in proof-of-concept trials.
    Pulkstenis E; Patra K; Zhang J
    J Biopharm Stat; 2017; 27(3):442-456. PubMed ID: 28166459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calculation, expression and perception of risk in medicine: implications for clinical decision-making.
    Costa J; Carneiro AV
    Rev Port Cardiol; 2011 Jan; 30(1):95-119. PubMed ID: 21425747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Going beyond probability of success: Opportunities for statisticians to influence quantitative decision-making at the portfolio level.
    Wiklund SJ; Thorn K; Götte H; Hacquoil K; Saint-Hilary G; Carlton A;
    Pharm Stat; 2024; 23(3):429-438. PubMed ID: 38212898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal Futility Interim Design: A Predictive Probability of Success Approach with Time-to-Event Endpoint.
    Tang Z
    J Biopharm Stat; 2015; 25(6):1312-9. PubMed ID: 25379701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.